Table 4.
Serum amyloid A immunohistochemistry
| Staining pattern | None (0%) | Focal/patchy (<80%) | Diffuse (≥80%) |
|---|---|---|---|
|
| |||
| N | 29 (39.2%) | 31 (41.9%) | 14 (18.9%) |
|
| |||
| Age (year) | 26–83 (median 69) | 32 – 80 (median 65) | 18–75 (median 59.5) |
|
| |||
| Male: Female | 18: 11 | 16: 15 | 10: 4 |
|
| |||
| Viral hepatitis or alcoholic liver disease | 3 | 2 | 0 |
|
| |||
| Diabetes mellitus | 5/22 (22.7%) | 6/30 (20.0%) | 5/13 (38.5%) |
|
| |||
| Body mass index (available n) | 19 | 23 | 12 |
|
| |||
| < 25 | 7 (36.8%) | 10 (43.5%) | 2 (16.7%) |
|
| |||
| 25 – 29 | 6 (31.6%) | 7 (30.4%) | 5 (41.7%) |
|
| |||
| ≥ 30 | 6 (31.6%) | 6 (26.1%) | 5 (41.7%) |
|
| |||
| Metabolic Syndrome | 4/4 (100.0%) | 6/13 (46.2%) | 5/9 (55.6%) |
|
| |||
| Size (cm)* | 1.3 – 19 (mean 7.9) | 1.5 – 13.5 (mean 6.8) | 2.2 – 24 (mean 11.4) |
|
| |||
| Multifocality | 8 (27.6%) | 9 (29.0%) | 3 (21.4%) |
|
| |||
| Tumor Grade | I: 1 (3.4%), | I: 5 (16.1%), | I: 4 (28.6%), |
| II: 15 (51.7%), | II: 13 (41.9%), | II: 7 (50.0%), | |
| III: 7 (24.1%), | III: 9 (29.0%), | III: 1 (7.1%), | |
| IV: 6 (20.7%) | IV: 4 (13.8%) | IV: 2 (14.3%) | |
|
| |||
| Steatosis (tumor) | 4 (13.8%) | 5 (16.1%) | 3 (21.4%) |
|
| |||
| Steatosis (liver)* | 2 (6.9%) | 8 (25.8%) | 5 (35.7%) |
|
| |||
| Fibrosis | 0: 10 (34.5%), | 0: 7 (22.6%), | 0: 4 (28.6%), |
| 1: 8 (27.6%), | 1: 5 (16.1%), | 1: 5 (35.7%), | |
| 2: 7 (24.1%), | 2: 16 (51.6%), | 2: 4 (28.6%), | |
| 3: 4 (13.8%) | 3: 3 (9.7%) | 3: 1 (7.1%) | |
*
p < 0.05.